This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gold, H. K. Articles by Collen, D. Search for Related Content PubMed PubMed Citation Articles by Gold, H. K. Articles by Collen, D.

Circulation, Vol 75, 1192-1199, Copyright © 1987 by American Heart Association

ARTICLES

A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris

HK Gold, JA Johns, RC Leinbach, T Yasuda, E Grossbard, R Zusman and D Collen

Twenty-four patients with unstable angina pectoris, defined as chest pain at rest with transient ST segment deviation of at least 1 mm, were randomly assigned to blinded treatment with either placebo or intravenous recombinant human tissue-type plasminogen activator (rt- PA). Before randomization, all patients were treated with oral beta- blockers, calcium antagonists, nitrates, and continuous intravenous heparin for a monitoring period of 12 to 28 hr. After this monitoring period the 24 patients were randomly assigned to receive either placebo or 1.75 mg/kg intravenous rt-PA given over 12 hr at a rate of 0.75 mg/kg over 1 hr, 0.5 mg/kg over 4 hr, and 0.5 mg/kg over 7 hr. One patient, assigned to receive placebo, developed acute myocardial infarction after randomization but before receiving the study drug. Ischemic events were recorded during a hospital follow-up period of at least 4 days unless a further intervention was indicated or the coronary angiogram was normal. The follow-up period was 7 +/- 5 days (mean +/- SD) after the placebo infusion and 8 +/- 4 days after the infusion of rt-PA. Unstable angina pectoris persisted after the completion of the infusion in six of 11 patients receiving placebo and only one of 12 patients receiving rt-PA (p less than .03). Coronary angiography, performed 38 +/- 19 hr after the infusion, demonstrated subocclusive thrombus in eight of 11 patients receiving placebo but in none of 11 patients treated with rt-PA (p less than .002). One patient on rt-PA refused coronary angiography.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				G. N. Levine, M. N. Ali, and A. I. Schafer Antithrombotic Therapy in Patients With Acute Coronary Syndromes Arch Intern Med, April 9, 2001; 161(7): 937 - 948. [Abstract] [Full Text] [PDF]

				D. W. M. Muller and E. J. Topol Selection of Patients with Acute Myocardial Infarction for Thrombolytic Therapy Ann Intern Med, December 15, 1990; 113(12): 949 - 960. [Abstract] [PDF]

				T. H. Lee, M. C. Weisberg, D. A. Brand, G. W. Rouan, and L. Goldman Candidates for Thrombolysis among Emergency Room Patients with Acute Chest Pain: Potential True- and False-Positive Rates Ann Intern Med, June 15, 1989; 110(12): 957 - 962. [Abstract] [PDF]

				E. Johnson and T. Ports Unstable Angina Pectoris: An Interventional Approach to Management J Intensive Care Med, July 1, 1988; 3(4): 202 - 214. [Abstract] [PDF]

				EFFECTS OF HUMAN TISSUE-TYPE PLASMINOGEN ACTIVATOR ON CORONARY THROMBOLYSIS Journal Watch (General), July 17, 1987; 1987(717): 1 - 1. [Full Text]